.webp)
Fakeeh University Hospital is rapidly emerging as a global destination for advanced gene therapy, delivering highly specialized and innovative treatments for rare genetic and neuromuscular disorders. This progress further reinforces Dubai’s position as a leading center for world-class tertiary and quaternary healthcare.
Among the hospital’s most significant milestones is becoming the first facility in the region to administer Duvyzat (givinostat)—an advanced therapeutic option used in the management of Duchenne muscular dystrophy (DMD).
DMD is a rare, inherited neuromuscular disorder that primarily affects young boys. It is characterized by progressive muscle weakness, gradual loss of mobility, and serious cardiac and respiratory complications as the disease advances. Without timely and specialized intervention, the condition can significantly impact both life expectancy and quality of life.
The introduction of Duvyzat at Fakeeh University Hospital represents a major advancement in regional care for DMD patients. Early diagnosis and access to cutting-edge therapies play a crucial role in slowing disease progression, preserving functional ability, and improving long-term outcomes.
By offering access to advanced gene-based and disease-modifying therapies, supported by multidisciplinary expertise and state-of-the-art infrastructure, Fakeeh University Hospital continues to attract patients from across the region and internationally—setting new standards in precision medicine and specialized care.
